T HERE IS little doubt that improved understanding of the genetic basis of disease will continue to produce considerable advances in patient care. Among the genetic tools finding greater application is whole exome sequencing.
Exons account for only 1.2% of a patient's total DNA but contain 85% of all disease-causing mutations found to date. 1, 2 Thus, sequencing all exons (the exome), rather than a person's entire genome, is more rapid (È2Y4 weeks) and cost-effective (È$1000 per person), with both parameters decreasing.
How are exomes sequenced? A patient's DNA is sheared into small fragments (È200 base pairs) and hybridized (bound) to prefabricated DNA probes. The hybridized exons are captured (again bound) by antibody-marked beads. These exons are then purified and amplified using polymerase chain reaction and finally sequenced using high-throughput sequencing machines.
How are mutations discovered from exome sequences? Exomes sequenced from the patient are mapped against a reference human genome, and deviations from the reference are identified (È10,000 per person). After excluding common variants known from control libraries, the remaining rare distinct variations become candidates for potentially diseasecausing mutations.
In which disorders of dermatologic significance has exome sequencing uncovered the genetic defect?
Familial cases of psoriasis were shown to have multiple activating mutations of CARD14 that cause enhanced activation of NF-JB. 3, 4 A case of oculocutaneous albinism and neutropenia was found to carry 2 gene mutations, SLCA5A2 and G6PC3. 5 Mutations of DHOHD cause Miller syndrome, a rare disorder comprised of eyelid coloboma, severe micrognathia, cleft lip/palate, supernumerary nipples, and hypoplasia or aplasia of the limbs. 6 What are the strengths and weaknesses of and alternative strategies to exome sequencing?
Exome sequencing is excellent for identifying causative genes of highly penetrant mendelian diseases and for identifying single-nucleotide variations.
However, it may miss variations in nontranscribed regions of the genome (ie, promoters and regulatory elements) and variations that lead to absent transcripts. It may not recognize deletions, duplications, or translocations of genomic DNA causing disease. Finally, it is unable to evaluate variations regulated epigenetically (eg, DNA methylation and histone modification).
Alternatives and complimentary approaches to identifying disease-causing genes include whole genomic sequencing, linkage analysis, searching for copy number variation, and epigenetic testing.
Ethical considerations raise the following questions Should patients have access to their sequencing information? How about insurance providers? Aside from the gene(s) of interest, what should be done with other unique sequence variations in a given individual?
